SeeThruEquity Initiates Coverage on Propanc Health Group with a Price Target of $1.52
Accesswire
3 hours ago
NEW YORK, NY / ACCESSWIRE / May 27, 2015 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced it has initiated coverage of Propanc Health Group Corp.. (PPCH) with a Price Target of $1.52.
The report is available here: PPCH Initiation Report. SeeThruEquity is an approved equity research contributor on Thomson First Call, Capital IQ, FactSet, and Zack's. The report will be available on these platforms. We also contribute our estimates to Thomson Estimates, the leading estimates platform on Wall Street.
"Propanc's pro-enzyme therapy- chiefly its lead drug candidate, PRP- aims to solve this problem by targeting malignant cancer cells through multiple pathways that creates a lasting clinical benefit for the patient. Propanc is now ready to complete the formal animal studies that precede the human trials planned for 2016. Upon commercialization, the drug will be marketed to oncologists across global territories for specific cancer indications aggregating a $9bn total addressable market," stated Ajay Tandon, CEO of SeeThruEquity. "We are initiating coverage with a 12-month price target of $1.52 per share."
Additional highlights from the report are as follows:
Developing a targeted therapy for metastatic cancer
Propanc's lead drug candidate, PRP, is a once-daily pro-enzyme treatment as a clinically proven therapeutic option in the treatment and prevention of cancer. PRP would be the first therapy of its kind, as there are no FDA approved therapies used for the long-term prevention or management of these conditions. Propanc is focusing on providing oncologists and their patients with more effective metastatic cancer therapies with a substantially reduced side effect profile; specifically, colorectal and pancreatic cancers. Improvement is needed for the standard of care for late stage cancer, with the incumbent treatments causing significant adverse effects for the modest benefits provided.
$9bn market opportunity with an unmet medical need
The rapidly aging population and changing environmental factors in Western countries have spearheaded growing demand for new cancer treatments with increased efficacy and reduced toxicity. Globally, total oncology drug sales are growing 5% annually and reached $91bn in 2013. Additionally, the targeted therapies market segment has substantially increased share over the past decade from 11% to 46%. Propanc is targeting patients with solid tumors- such as colorectal and pancreatic tumors. The total addressable market is estimated to be $7.8bn in 6 years for colorectal cancer, and is expected to grow to $1.63bn by 2017 for pancreatic cancer.
Potential strategic partnership post clinical trial(s)
Propanc is seeking potential licensing partners within the next 12-18 months and the Company is also investigating acquisition opportunities that will expedite their strategic growth and strengthen their portfolio. Company management has stated that once the development projects have sufficiently progressed down the development pathway and have commensurately achieved a major increase in value, they will seek a suitable licensing partner to complete the remaining development activities, obtain regulatory approval and market the product.
Unique intellectual property portfolio with ongoing expansion
Propanc recently filed an international patent application centered on enhancing pro-enzyme formulations and combination therapies comprising trypsinogen and chymotrypsin, and/or other specific anti-cancer agents.
Accesswire
3 hours ago
NEW YORK, NY / ACCESSWIRE / May 27, 2015 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced it has initiated coverage of Propanc Health Group Corp.. (PPCH) with a Price Target of $1.52.
The report is available here: PPCH Initiation Report. SeeThruEquity is an approved equity research contributor on Thomson First Call, Capital IQ, FactSet, and Zack's. The report will be available on these platforms. We also contribute our estimates to Thomson Estimates, the leading estimates platform on Wall Street.
"Propanc's pro-enzyme therapy- chiefly its lead drug candidate, PRP- aims to solve this problem by targeting malignant cancer cells through multiple pathways that creates a lasting clinical benefit for the patient. Propanc is now ready to complete the formal animal studies that precede the human trials planned for 2016. Upon commercialization, the drug will be marketed to oncologists across global territories for specific cancer indications aggregating a $9bn total addressable market," stated Ajay Tandon, CEO of SeeThruEquity. "We are initiating coverage with a 12-month price target of $1.52 per share."
Additional highlights from the report are as follows:
Developing a targeted therapy for metastatic cancer
Propanc's lead drug candidate, PRP, is a once-daily pro-enzyme treatment as a clinically proven therapeutic option in the treatment and prevention of cancer. PRP would be the first therapy of its kind, as there are no FDA approved therapies used for the long-term prevention or management of these conditions. Propanc is focusing on providing oncologists and their patients with more effective metastatic cancer therapies with a substantially reduced side effect profile; specifically, colorectal and pancreatic cancers. Improvement is needed for the standard of care for late stage cancer, with the incumbent treatments causing significant adverse effects for the modest benefits provided.
$9bn market opportunity with an unmet medical need
The rapidly aging population and changing environmental factors in Western countries have spearheaded growing demand for new cancer treatments with increased efficacy and reduced toxicity. Globally, total oncology drug sales are growing 5% annually and reached $91bn in 2013. Additionally, the targeted therapies market segment has substantially increased share over the past decade from 11% to 46%. Propanc is targeting patients with solid tumors- such as colorectal and pancreatic tumors. The total addressable market is estimated to be $7.8bn in 6 years for colorectal cancer, and is expected to grow to $1.63bn by 2017 for pancreatic cancer.
Potential strategic partnership post clinical trial(s)
Propanc is seeking potential licensing partners within the next 12-18 months and the Company is also investigating acquisition opportunities that will expedite their strategic growth and strengthen their portfolio. Company management has stated that once the development projects have sufficiently progressed down the development pathway and have commensurately achieved a major increase in value, they will seek a suitable licensing partner to complete the remaining development activities, obtain regulatory approval and market the product.
Unique intellectual property portfolio with ongoing expansion
Propanc recently filed an international patent application centered on enhancing pro-enzyme formulations and combination therapies comprising trypsinogen and chymotrypsin, and/or other specific anti-cancer agents.
选择“Disable on www.wenxuecity.com”
选择“don't run on pages on this domain”
